Literature DB >> 21247346

Lentiviral vectors targeted to MHC II are effective in immunization.

Alexander Ageichik1, Christian J Buchholz, Mary K Collins.   

Abstract

Abstract vectors (LVs) that are targeted to APC using a chimeric measles virus (MV) hemagglutinin (H). The MV H protein is mutated to prevent binding to MV receptors and incorporates a single-chain antibody that recognizes murine major histocompatibility complex class II (MHC II). This targeted LV is highly efficient in transduction of freshly isolated mouse B cells and dendritic cells. MHC II-positive cells in spleen are transduced after intravenous injection, and a robust immune response to an antigen transgene is generated.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21247346     DOI： 10.1089/hum.2010.184

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


  17 in total

1.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

2.  Targeting of human antigen-presenting cell subsets.

Authors:  Cleo Goyvaerts; Jozef Dingemans; Kurt De Groeve; Carlo Heirman; Ellen Van Gulck; Guido Vanham; Patrick De Baetselier; Kris Thielemans; Geert Raes; Karine Breckpot
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

3.  CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells.

Authors:  Sarah-Katharina Kays; Kerstin B Kaufmann; Tobias Abel; Christian Brendel; Halvard Bonig; Manuel Grez; Christian J Buchholz; Sabrina Kneissl
Journal:  Stem Cells Dev       Date:  2015-01-20       Impact factor: 3.272

4.  Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.

Authors:  C Goyvaerts; Y De Vlaeminck; D Escors; S Lienenklaus; M Keyaerts; G Raes; K Breckpot
Journal:  Gene Ther       Date:  2017-05-25       Impact factor: 5.250

5.  In Vivo Gene Delivery to Lymph Node Stromal Cells Leads to Transgene-specific CD8+ T Cell Anergy in Mice.

Authors:  Séverine Ciré; Sylvie Da Rocha; Maxime Ferrand; Mary K Collins; Anne Galy
Journal:  Mol Ther       Date:  2016-08-26       Impact factor: 11.454

6.  Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.

Authors:  Paul D Bryson; Xiaolu Han; Norman Truong; Pin Wang
Journal:  Vaccine       Date:  2017-09-12       Impact factor: 3.641

7.  Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells.

Authors:  Camille Lévy; Fouzia Amirache; Caroline Costa; Cecilia Frecha; Claude P Muller; Hasan Kweder; Robin Buckland; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

8.  Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Authors:  Katharina M Uhlig; Stefan Schülke; Vivian A M Scheuplein; Anna H Malczyk; Johannes Reusch; Stefanie Kugelmann; Anke Muth; Vivian Koch; Stefan Hutzler; Bianca S Bodmer; Axel Schambach; Christian J Buchholz; Zoe Waibler; Stephan Scheurer; Michael D Mühlebach
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

9.  The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function.

Authors:  Anke Rasbach; Tobias Abel; Robert C Münch; Klaus Boller; Jürgen Schneider-Schaulies; Christian J Buchholz
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 10.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.